Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
10.4093/dmj.2015.39.4.342
- Author:
Shusuke YAGI
1
;
Ken Ichi AIHARA
;
Masashi AKAIKE
;
Daiju FUKUDA
;
Hotimah Masdan SALIM
;
Masayoshi ISHIDA
;
Tomomi MATSUURA
;
Takayuki ISE
;
Koji YAMAGUCHI
;
Takashi IWASE
;
Hirotsugu YAMADA
;
Takeshi SOEKI
;
Tetsuzo WAKATSUKI
;
Michio SHIMABUKURO
;
Toshio MATSUMOTO
;
Masataka SATA
Author Information
1. Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. syagi@tokushima-u.ac.jp
- Publication Type:Original Article
- Keywords:
Coronary artery disease;
Diabetes mellitus;
Dipeptidyl-peptidase IV inhibitors;
Obese;
Predictive factors
- MeSH:
Blood Glucose;
Body Mass Index;
Coronary Artery Disease;
Diabetes Mellitus;
Diabetes Mellitus, Type 2*;
Dipeptidyl-Peptidase IV Inhibitors;
Hemoglobin A, Glycosylated;
Humans;
Retrospective Studies;
Treatment Outcome
- From:Diabetes & Metabolism Journal
2015;39(4):342-347
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment. METHODS: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3+/-35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively. RESULTS: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167+/-63 to 151+/-49 mg/dL (P<0.01), and from 7.5%+/-1.3% to 6.9%+/-0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease. CONCLUSION: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.
